Emerging Drug Developer: TransMolecular
There's one key point that the CEO of Cambridge, MA-based TransMolecular wants everyone to know up front.
"We are not using scorpion venom," says Michael Egan "It is one peptide in 40 in the mix of the venom."
For a biotech audience, that won't be too startling a revelation. But you'd be surprised how often it comes up, he says, in the stories that cover the company's efforts.
TransMolecular has a very narrow focus that covers a broad range of cancer therapies. Starting with research from the University of Alabama, the developer has been advancing TM601, which has the uncommon ability to bind and intrude into a tumor cell. And the implications that they had a new therapy that could act as an independent delivery agent, or perhaps even work as a therapeutic on its own, has consumed the company. Article
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
